Original Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 28, 2013; 19(8): 1219-1229
Published online Feb 28, 2013. doi: 10.3748/wjg.v19.i8.1219
Table 5 Comparison of nonalcoholic fatty liver disease patients alive vs deceased n (%) (mean ± SD)
VariablesNAFLD patients alive (n = 263)NAFLD patients deceased (n = 39)P value
At baseline
Age (yr)45.2 ± 11.561.1 ± 13.8< 0.0001
Sex (% male)120 (45.6)12 (30.8) 0.08
History of diabetes37 (14.1)11 (28.2) 0.02
Systolic blood pressure (mmHg)134 ± 17143 ± 21 0.02
Diastolic blood pressure (mmHg)83 ± 879 ± 10 0.03
Glucose (mg/dL)112 ± 38.6132.7 ± 54.3 0.03
AST (U/L)42.2 ± 25.535.5 ± 20.0 0.06
ALT (U/L)64.2 ± 44.643.6 ± 27.4 0.000
AST/ALT ratio0.8 ± 0.41.0 ± 0.7 0.06
Albumin (g/dL)4.3 ± 0.34.0 ± 0.4< 0.0001
FRS7.9 ± 6.211.4 ± 5.2 0.000
Calculated CHD risk (%)15.3 ± 14.022.2 ± 17.1 0.02
NFS-1.9 ± 1.3-0.8 ± 1.7 0.0004
NFS of intermediate or high probability of advanced liver fibrosis (%)94 (35.7)27 (69.2)< 0.0001
Presence of histologically advanced liver fibrosis7/35 (20.0)5/11 (45.5) 0.09
During the follow-up period77 (29.3)3 (7.7) 0.004
Use of metformin
Use of aspirin151 (57.4)16 (41.0) 0.05
Use of simvastatin107 (40.7)3 (7.9)< 0.0001
New events of coronary heart disease16 (6.1)14 (35.9)< 0.0001
Liver complications1 (0.4)5 (12.8)< 0.0001
At the end of follow-up
BMI (kg/m2)33.9 ± 6.931.8 ± 8.2 0.1
Hematocrit (%)40.4 ± 4.134.5 ± 6.3< 0.0001
Glucose (mg/dL)122.0 ± 38.6139.0 ± 62.3 0.12
AST/ALT ratio0.9 ± 0.51.3 ± 1.0 0.01
Albumin (g/dL)4.1 ± 0.33.3 ± 0.7< 0.0001
Creatinine (mg/dL)1.0 ± 0.51.7 ± 1.3 0.004
NFS-0.9 ± 1.40.7 ± 2.3< 0.0001
NFS change per year (Median; IQR)0.07 (0.02, 0.12)0.14 (0.01, 0.31) 0.03
NFS of intermediate to high probability of advanced liver fibrosis (%)168 (63.9)31 (79.5) 0.05